A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Chi, Hsin ^a,b,c,d   Hsu, Chyong Hsin ^a   Chang, Jui Hsing ^a   Chiu, Nan Chang ^a,c   Hung, Han Yang ^a   Kao, Hsin An ^a   Weng, Li Chuan ^a   Huang, Fu Yuan ^a   Chiu, Yu Ying ^a   Chang, Luan Yin ^b,e   Huang, Li Min ^b,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; GESTATIONAL AGE; HEAT SENSATION; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; INTENSIVE CARE; IRRITABILITY; LENGTH OF STAY; MALE; PAIN; PATIENT COMPLIANCE; PREMATURITY; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINORRHEA; SURVIVAL RATE; SWELLING; TAIWAN; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMOPROPHYLAXIS; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; NEWBORN; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHEMOPREVENTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 84903384822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100981     Document Type: Article

References (40)

1. Hall CB (2010) Respiratory Syncytial Virus. In: Mandell GL BJ, Dolin R, editor. Principles and Practice of Infectious Diseases. 7 ed. New York: Churchill Livingstone Inc. 2207-2221.
2. Simoes EA (1999) Respiratory syncytial virus infection. Lancet 354: 847-852.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, et al. (1999) Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282: 1440-1446. (Pubitemid 29493797)
4. Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, et al. (2006) Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 134: 506-513.
5. Chi H, Chang IS, Tsai FY, Huang LM, Shao PL, et al. (2011) Epidemiological study of hospitalization associated with respiratory syncytial virus infection in Taiwanese children between 2004 and 2007. J Formos Med Assoc 110: 388-396.
6. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598.
7. Sommer C, Resch B, Simoes EA (2011) Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 5: 144-154.
8. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA (1999) Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 104: 894-899. (Pubitemid 29463557)
9. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, et al. (2000) Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 19: 592-597. (Pubitemid 30469763)
10. Underwood MA, Danielsen B, Gilbert WM (2007) Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 27: 614-619. (Pubitemid 47491471)
11. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224. (Pubitemid 27460986)
12. American Academy of Pediatrics, Committee on Infectious Diseases and Committee of Fetus and Newborn (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102: 1211-1216.
13. American Academy of Pediatrics, Committee on Infectious Diseases and Committee of Fetus and Newborn (2003) Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112: 1442-1446.
14. American Academy of Pediatrics, Committee on Infectious Diseases and Committee of Fetus and Newborn (2009) Policy statements - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124: 1694-1701.
15. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, et al. (2007) Influenza- and RSV-associated hospitalizations among adults. Vaccine 25: 846-855. (Pubitemid 44873160)
16. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW (2006) Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 160: 1070-1076. (Pubitemid 44520638)
17. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, et al. (2004) Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 114: 1612-1619. (Pubitemid 41754927)
18. Loscertales MP, Roca A, Ventura PJ, Abacassamo F, Dos Santos F, et al. (2002) Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. Pediatr Infect Dis J 21: 148-155. (Pubitemid 34150614)
19. Stensballe LG, Devasundaram JK, Simoes EA (2003) Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 22: S21-32. (Pubitemid 36228149)
20. Meissner HC, Anderson LJ, Pickering LK (2004) Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab. Pediatrics 114: 1082-1084. (Pubitemid 41529776)
21. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, et al. (2007) Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 166: 1267-1272. (Pubitemid 350029479)
22. Lee JT, Chang LY, Wang LC, Kao CL, Shao PL, et al. (2007) Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 - seasonality, clinical characteristics, and disease burden. J Microbiol Immunol Infect 40: 293-301.
23. Tsai HP, Kuo PH, Liu CC, Wang JR (2001) Respiratory viral infections among pediatric inpatients and outpatients in Taiwan from 1997 to 1999. J Clin Microbiol 39: 111-118.
24. Austin PC (2008) Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 17: 1218-1225.
25. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, et al. (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28: 511-517. (Pubitemid 351973995)
26. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, et al. (2007) Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 42: 189-192. (Pubitemid 46417688)
27. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22: 823-827. (Pubitemid 37153079)
28. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC (2003) Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 22: 540-545. (Pubitemid 36782194)
29. The IMpact-RSV Study Group (1998) Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 102: 531-537.
30. Saez-Llorens X, Moreno MT, Ramilo O, Sanchez PJ, Top FH Jr, et al. (2004) Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 23: 707-712. (Pubitemid 39063284)
31. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK (2012) Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 56: 4927-4936.
32. Fryzek JP, Martone WJ, Groothuis JR (2011) Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Adv Ther 28: 195-201.
33. Bont L, Houben ML (2011) Commentary: why are young healthy term infants protected against respiratory syncytial virus bronchiolitis? Pediatr Infect Dis J 30: 785-786.
34. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR (2000) Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 137: 865-870.
35. Chew FT, Doraisingham S, Ling AE, Kumarasinghe G, Lee BW (1998) Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 121: 121-128. (Pubitemid 28423337)
36. Chan PW, Chew FT, Tan TN, Chua KB, Hooi PS (2002) Seasonal variation in respiratory syncytial virus chest infection in the tropics. Pediatr Pulmonol 34: 47-51. (Pubitemid 34686711)
37. Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, et al. (2007) The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect 135: 1077-1090. (Pubitemid 47487593)
38. Romero JR (2003) Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 22: S46-54.
39. Mitchell I, Paes BA, Li A, Lanctot KL (2011) CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 30: 651-655.
40. Groothuis JR (2001) Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. Pediatr Infect Dis J 20: 628-630.